Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation

Journal of Clinical Investigation

Volumn 124, Issue 2, 2014, Pages 580-591

  Bluteau, Dominique ^a,b,c,d   Balduini, Alessandra ^e   Balayn, Nathalie ^a,b,c   Currao, Manuela ^e   Nurden, Paquita ^f,g   Deswarte, Caroline ^a,h   Leverger, Guy ^a,h,i   Noris, Patrizia ^e   Perrotta, Silverio ^j   Solary, Eric ^a,b,c   Vainchenker, William ^a,b,c   Debili, Najet ^a,b,c   Favier, Remi ^a,i   Raslova, Hana ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d PSL RESEARCH UNIVERSITY   (France)

^e UNIVERSITY OF PAVIA   (Italy)

^f Ctr Geriatrie Ctr Hosp Univ B   (France)

^g TIMONE HOSPITAL   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^j SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5' UNTRANSLATED REGIONS; ADOLESCENT; ADULT; BASE SEQUENCE; BINDING SITES; CELL DIFFERENTIATION; CHROMOSOME BREAKAGE; CHROMOSOME DISORDERS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; INFANT; MALE; MAP KINASE SIGNALING SYSTEM; MEGAKARYOCYTES; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; PEDIGREE; PROTO-ONCOGENE PROTEIN C-FLI-1; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84893875673     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI71861     Document Type: Article

References (39)

1. Noris P, et al. Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families. Blood. 2011;117(24):6673-6680.
2. Noris P, et al. ANKRD26-related thrombocytopenia myeloid malignancies. Blood. 2013; 122(11):1987-1989.
3. Savoia A, et al. An autosomal dominant thrombocytopenia gene maps to chromosomal region 10p. Am J Hum Genet. 1999;65(5):1401-1405.
4. Drachman JG, Jarvik GP, Mehaffey MG. Autosomal dominant thrombocytopenia: incomplete megakaryocyte differentiation linkage to human chromosome 10. Blood. 2000;96(1):118-125.
5. Pippucci T, et al. Mutations in the 5βUTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet. 2011; 88(1):115-120.
6. Necchi V, et al. Ubiquitin/proteasome-rich particulate cytoplasmic structures (PaCSs) in the platelets and megakaryocytes of ANKRD26-related thrombocytopenia. Thromb Haemost. 2013;109(2):263-271.
7. Hahn Y, Bera TK, Pastan IH, Lee B. Duplication and extensive remodeling shaped POTE family genes encoding proteins containing ankyrin repeat and coiled coil domains. Gene. 2006;366(2):238-245.
8. Raciti GA, Bera TK, Gavrilova O, Pastan I. Partial inactivation of Ankrd26 causes diabetes with enhanced insulin responsiveness of adipose tissue in mice. Diabetologia. 2011;54(11):2911-2922.
9. Fei Z, Bera TK, Liu X, Xiang L, Pastan I. Ankrd26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. J Biol Chem. 2011; 286(31):27761-27768.
10. Thomas-Chollier M, et al. Transcription factor binding predictions using TRAP for the analysis of ChIP-seq data and regulatory SNPs. Nat Protoc. 2011; 6(12):1860-1869.
11. Marinescu VD, Kohane IS, Riva A. MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics. 2005;6:79.
12. Huang H, et al. Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol. 2009; 29(15):4103-4115.
13. Börsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem. 1998;273(44):28766- 28772.
14. Sabri S, et al. Differential regulation of actin stress fiber assembly and proplatelet formation by α2β1 integrin and GPVI in human megakaryocytes. Blood. 2004;104(10):3117-3125.
15. Besancenot R, et al. A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. PLoS Biol. 2010; 8(9).pii:e1000476.
16. Minamiguchi H, et al. Simultaneous signalling through c-mpl, c-kit and CXCR4 enhances the proliferation and differentiation of human megakaryocyte progenitors: possible roles of the PI3-K, PKC, and MAPK pathways. Br J Haematol. 2001; 115(1):175-185.
17. Ludlow LB, et al. Identification of a mutation in a GATA binding site of the platelet glycoprotein Ibbeta promoter resulting in the Bernard-Soulier syndrome. J Biol Chem. 1996;271(36):22076-22080.
18. Albers CA, et al. Compound inheritance of a lowfrequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet. 2012;44(4):435-439.
19. Tijssen MR, et al. Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell. 2011;20(5):597-609.
20. Lordier L, et al. RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. Nat Commun. 2012;3:717.
21. Antony-Debré I, et al. MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. Blood. 2012;120(13):2719-2722.
22. Yu M, et al. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell. 2012;45(3):330-343.
23. Fichelson S, et al. Megakaryocyte growth and development factor-induced proliferation and differentiation are regulated by the mitogen-activated protein kinase pathway in primitive cord blood hematopoietic progenitors. Blood. 1999; 94(5):1601-1613.
24. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood. 1999;94(4):1273-1282.
25. Guerriero R, et al. Inhibition of TPO-induced MEK or mTOR activity induces opposite effects on the ploidy of human differentiating megakaryocytes. J Cell Sci. 2006;119(pt 4):744-752.
26. Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS, Ahn NG. Megakaryocytic differentiation induced by constitutive activation of mitogenactivated protein kinase kinase. Mol Cell Biol. 1997; 17(4):1947-1958.
27. Herrera R, Hubbell S, Decker S, Petruzzelli L. A role for the MEK/MAPK pathway in PMA-induced cell cycle arrest: modulation of megakaryocytic differentiation of K562 cells. Exp Cell Res. 1998; 238(2):407-414.
28. Racke FK, Lewandowska K, Goueli S, Goldfarb AN. Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells. J Biol Chem. 1997;272(37):23366-23370.
29. Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F. Control of thrombopoietininduced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol. 1997;17(9):4991-5000.
30. Mazharian A, Watson SP, Séverin S. Critical role for ERK1/2 in bone marrow and fetal liverderived primary megakaryocyte differentiation, motility, and proplatelet formation. Exp Hematol. 2009;37(10):1238-1249.
31. Liu XF, et al. ANKRD26 and its interacting partners TRIO, GPS2, HMMR and DIPA regulate adipogenesis in 3T3-L1 cells. PLoS One. 2012;7(5):e38130.
32. Flaherty KT, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
33. Debili N, Massé JM, Katz A, Guichard J, Breton-Gorius J, Vainchenker W. Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells. Blood. 1993;82(1):84-95.
34. Balduini A, et al. Proplatelet formation in heterozygous Bernard-Soulier syndrome type Bolzano. J Thromb Haemost. 2009;7(3):478-484.
35. Bluteau D, et al. Dysmegakaryopoiesis of FPD/ AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood. 2012;120(13):2708-2718.
36. Gilles L, et al. P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. Blood. 2008;111(8):4081-4091.
37. Bluteau D, et al. Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. Blood. 2011;118(24):6310-6320.
38. Komura E, et al. Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression. Exp Hematol. 2003;31(7):622-630.
39. Nurden P, et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood. 2006;108(8):2587-2595.